Texas Lifesciences Private Limited
Texas Lifesciences Private Limited is a Private Non-govt company company incorporated in 2017 and based in Gujarat, India. It was founded by Kamleshkumar. Texas Lifesciences Private Limited operates in Manufacture of synthetic filament yarn, whether or not textured, high tenacity, (NIC 24304) with authorized capital of ₹6.31 Cr and paid-up capital of ₹4.94 Cr. For 2022-23, the company reported revenue of ₹26.66 Cr and profit after tax of ₹1.47 Cr. The board has 2 active directors. RegisterKaro's provisional Compliance Health Score for the company is 100/100 (grade A), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
TEXAS LIFESCIENCES PRIVATE LIMITED is the legal entity of Hester Biosciences.
Quick facts
Directors
2 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | +30d | filed |
| MGT-7 | FY2024-25 | 23 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 25 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 26 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Texas Lifesciences Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 488045369 | ICICI Bank Ltd(Bank) | ₹85.04 L | 04 Jul 2019 | Satisfied |
| 668993303 | ICICI Bank Ltd(Bank) | ₹8.95 Cr | 12 Mar 2019 | Satisfied |
| 807071802 | ICICI Bank Ltd(Bank) | ₹20.20 Cr | 27 Jan 2023 | Open |
| 887091688 | Axis Bank Ltd(Bank) | ₹24.22 Cr | 27 Jan 2020 | Satisfied |
| 605997585 | Axis Bank Ltd(Bank) | ₹9.71 Cr | 27 Jan 2023 | Satisfied |
Charge IDs, lenders & amounts for Texas Lifesciences Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2022-23 | — | ||||
| 2021-22 | — | ||||
| 2020-21 | — | ||||
| 2019-20 | — | ||||
| 2018-19 | — | ||||
| 2017-18 | — |
Detailed Financials
4 FYs| Line item | 2022-23 | 2021-22 | 2020-21 | 2019-20 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2022-23 | -4.0% | +47.0% | +59.0% | |
| Profit after Tax2022-23 | -1.0% | +52.0% | +858.0% | |
| Net Worth2022-23 | +29.0% | +91.0% | +60.0% |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2017-18 | +3.07% | — | +1.07% | +0.84% | 0.27 | |||
| 2018-19 | +5.00% | +468.27% | +9.02% | +6.69% | 0.35 | |||
| 2019-20 | +7.94% | +53.34% | +18.01% | +12.09% | 0.49 | |||
| 2020-21 | +7.48% | +40.60% | +15.85% | +10.42% | 0.52 | |||
| 2021-22 | +5.16% | +59.13% | +18.27% | +9.11% | 1.00 | |||
| 2022-23 | +5.50% | -6.92% | +15.34% | +7.87% | 0.95 |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 1 | 28,35,417 | 59.63% |
| Institutional Investors | 3 | 4,16,223 | 8.75% |
| Public & Others | 22 | 15,03,240 | 31.61% |
Promoter, institutional & public holding for Texas Lifesciences Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
63 peersTop 10 in Manufacture of synthetic filament yarn, whether or not textured, high tenacity,
by healthView all ›Events & timeline
3External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.